REG - Cambridge Cognition - Appointment of Nominated Adviser and Joint Broker

Cambridge Cognition HoldingsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260407:nRSG3410Za&default-theme=true

RNS Number : 3410Z  Cambridge Cognition Holdings PLC  07 April 2026

7 April 2026

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Appointment of Nominated Adviser and Joint Broker

Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology
company whose digital cognitive assessments drive scientific discovery,
accelerate drug development and improve patient care, announces the
appointment of Cavendish Capital Markets Limited as the Company's Nominated
Adviser and Joint Broker with immediate effect.

Singer Capital Markets remain in their role as Joint Corporate Broker.

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                            Tel: 01223 810700

 Rob Baker, Chief Executive Officer                          press@camcog.com (mailto:press@camcog.com)

 Ronald Openshaw, Chief Financial Officer

 Cavendish Capital Markets Limited (NOMAD and Joint Broker)  Tel: 020 7220 0500

 Geoff Nash / Elysia Bough / Joe Smith                       Corporate Finance

 Harriet Ward                                                Corporate Broking

 Nigel Birks                                                 LS Specialist Sales

 Singer Capital Markets Limited (Joint Broker)               Tel: 020 7496 3000

 Amber Higgs / James Serjeant / Daniel Ingram

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a neuroscience technology company whose digital
cognitive assessments drive scientific discovery, accelerate drug development
and improve patient care.

 

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health.  The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

 

 * Clinical Studies for new pharmaceuticals;

 * Academic Research for scientists to understand CNS disorders;

 * Healthcare to provide physicians with cognitive assessments to allow them to
diagnose and treat patients; and,

 * Consumer Health & Wellness to provide individuals access to accurate,
reliable, and meaningful data to assess their cognitive health.

 

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

Existing Board - AIM Rule 17 Disclosure

The Company confirms the following director disclosures pursuant to AIM Rule
17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

Steven Powell (Chairman)

Ribonexus SAS, a company which Steven Powell is a director of, entered into a
court-ordered liquidation in April 2024. The Company is currently still in
liquidation.

Steven was previously a director of LCC Therapeutics, resigning on 17 June
2025. After he had left employment, the company appointed an administrator and
later entered into a creditors voluntary liquidation on 16 October 2025. The
Company is currently still in liquidation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPUPUMPCUPQGMP



            Copyright 2019 Regulatory News Service, all rights reserved